Type 2 diabetes patients on Ozempic and Wegovy -- which contain the active ingredient semaglutide -- were 15% less likely to suffer bone fractures than those on other weight-loss drugs, researchers say.
Type 2 diabetes patients taking Ozempic and Wegovy may be getting an unexpected perk: a little extra backbone.
A new study suggests semaglutide — the active ingredient in the blockbuster weight-loss drugs — could help strengthen bones in type 2 diabe... [1667 chars]